2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic analogue of growth hormone–releasing hormone (GHRH) engineered to extend the duration of pulsatile growth hormone (GH) stimulation [1].
While short-acting GHRH analogues mimic the body’s natural rhythm in brief intervals, the DAC modification enables CJC-1295 to bind covalently to circulating albumin, dramatically increasing its half-life and sustaining its physiologic influence for days rather than hours [2].
This stability allows for consistent signaling through the GH–IGF-1 axis, which plays a central role in growth, tissue maintenance, and metabolic regulation [3].
This 30 amino acid peptide retains features of native GHRH but incorporates amino-acid substitutions that enhance resistance to enzymatic breakdown. When combined with DAC, these modifications create a formulation capable of maintaining elevated IGF-1 levels with infrequent administration.
CJC-1295 can provide extended support to endocrine pathways involved in cellular repair, lean-mass maintenance, and metabolic homeostasis.
The DAC modification helps the peptide to form a stable covalent bond with serum albumin, significantly prolonging its half-life compared to non-DAC formulations.
This prolonged activity allows for more sustained elevations in circulating IGF-1, a key mediator of anabolic and metabolic processes.
IGF-1 plays essential roles in protein synthesis, cellular repair, mitochondrial function, and nutrient partitioning. By maintaining higher IGF-1 concentrations over several days, CJC-1295 with DAC provides a longer, smoother signaling window that may enhance the body’s ability to support tissue maintenance and energy balance.
While short-acting GHRH analogues rely on frequent dosing to achieve measurable changes, the DAC-bound version generates a more gradual and durable physiological response.
This extended profile can:
While preserving the rhythmic qualities of GH secretion and broadening the duration of downstream effects.
An interventional clinical study of healthy adult men evaluated the effects of CJC-1295 on GH secretion parameters [4].
Participants received either 60 μg/kg or 90 μg/kg of a single subcutaneous injection of CJC-1295 with DAC. Participants then underwent 20-minute interval blood sampling over 12 hours overnight to characterize GH pulsatility.
Results showed that:
A single dose of CJC-1295 significantly increases basal (trough) GH secretion, leading to higher mean GH and IGF-1 levels, while keeping pulsatility intact.
CJC-1295 with DAC’s extended influence on the GH–IGF-1 axis can create a metabolic and anabolic environment that supports favorable shifts in body composition.
Growth hormone plays a central role in nutrient partitioning, encouraging the body to utilize fat as an energy substrate while preserving lean tissue. Through its prolonged stimulation of GH release and sustained elevation of IGF-1, CJC-1295 with DAC can reinforce pathways associated with [5]:
IGF-1 is particularly significant in this context, as it is involved in regulating:
By maintaining more consistent IGF-1 levels over time, CJC-1295 with DAC may help the body support muscle maintenance and gradual increases in lean mass, especially when combined with resistance training or periods of heightened physical demand.
Currently however, no human trials exist that evaluate these potential effects. A previous study did attempt to characterize whether CJC 1295 can reduce visceral fat in HIV patients with pathologic lipodystrophy [8].
However, after the death of a participant due to HIV itself, the trial was discontinued, with no data published.
Although there is some volume of anecdotal evidence of online users self-administering CJC 1295 for weight loss, regulated human studies need to be established to validate these theoretical applications.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). CJC 1295 with DAC is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
CJC-1295 is listed as a growth hormone-releasing hormone (GHRH) analogue, available in a form with Drug Affinity Complex (DAC) and a form without DAC. It is also described as a synthetic growth hormone analogue, based on an study of Internet forum activity about female use of the compound.
CJC-1295 is a peptide-based drug that stimulates the production of growth hormone (GH) from the pituitary gland. One description calls it a 30 amino acid peptide-based drug that stimulates the release of growth hormone from the pituitary gland. These statements describe its general action and do not name a particular study or species.
CJC-1295 is described as a peptide-based drug that stimulates the production of growth hormone from the pituitary gland. It is further described as a 30 amino acid peptide-based drug that stimulates the release of growth hormone from the pituitary gland. It is also referred to as a synthetic growth hormone analogue.
CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue, listed in two forms: with and without Drug Affinity Complex (DAC). The compound is described as incorporating a maleimido group at the C-terminus that allows it to covalently bind plasma proteins such as serum albumin. In a human clinical trial, CJC-1295-protein conjugates had a much greater half-life than the unconjugated peptide and stimulated GH production for more than six days after a single administration.
A review found that human clinical data on the peptides were limited to a handful of investigations, most lacking robust controls or rigorous study designs. The same review noted that CJC-1295 remains accessible through unregulated markets, raising concerns about product quality, dosing variability, and incompletely characterized adverse effects. On this evidence, the available material does not establish that CJC-1295 is safe.
The facts state that growth hormone-releasing hormone (GHRH) and its synthetic analogs, which include CJC-1295, are considered performance-enhancing substances and are prohibited by the World Anti-Doping Agency (WADA). The use of GHRHs, the class to which CJC-1295 belongs, is described as prohibited in sports under WADA regulations. CJC-1295 is listed, together with GHRH and the analogues sermorelin and tesamorelin, on the prohibited list of the World Antidoping Agency.
In laboratory method development, liquid chromatography-tandem mass spectrometry was used to detect CJC-1295 and related peptides in urine, with detection limits generally 1 ng/ml or less. In a laboratory validation study using human urine, one validated method used an immunopurification step with magnetic beads, then liquid chromatography-high resolution mass spectrometry, with a limit of detection of 0.2 ng/mL and a limit of identification of 0.5 ng/mL. A separate nano-LC-Q/Orbitrap mass spectrometry method, validated per WADA guidelines for target peptides including CJC-1295, reached detection limits of 0.5 ng/mL or lower and identification limits of 0.5-0.75 ng/mL in urine.
CJC-1295 in equine plasma has been detected with a previously described screening procedure that uses an immuno-PCR assay. In equine plasma, CJC-1295 was confirmed by LC-MS/MS after immuno-affinity capture and tryptic digestion, and was identified down to concentrations as low as 180 pg/mL in 1 mL of equine plasma. Because endogenous equine GHRH was detected, a screening threshold of 50 pg/mL for CJC-1295 in equine plasma was needed.
In mice with glucocorticoid-induced muscle loss, CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension, a measure of muscle force. This result was observed in murine models, and the study reports it only in animals.
In a human clinical trial, Cjc 1295-protein conjugates were capable of stimulating growth hormone production for more than six days after a single administration. This finding concerns the protein-conjugated form of Cjc 1295, which has a much greater half-life than the unconjugated peptide. A separate observation, with no species specified, is that once conjugated, Cjc 1295 remains active in the bloodstream for significantly longer than non-conjugated peptide-based drugs that are rapidly excreted.
In an observational study of people, female users of CJC-1295 described concerns about the consequences of their use. They linked these concerns to gender variations in growth hormone pulses, which affect estimating dosage, cycling, and long-term consequences. A human review concluded that public health efforts could take into account female self-medicating use of synthetic growth hormone, including CJC-1295, along with related adverse health consequences.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.